Prostate Cancer Clinical Trials in Philadelphia

Showing 161-180 of 201 trials

Study of Recurrent Prostate Cancer With Rising Prostate Specific Antigen (PSA)

NCT01118741

disulfiram is a DNA methyltransferase inhibitor that may provide benefit for patients with prostate cancer by restoring tumor suppressor genes.

Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins19 participantsStarted May 2010

Baltimore, Maryland, United States • Durham, North Carolina, United States • Philadelphia, Pennsylvania, United States

COMPLETEDPHASE1< 1 mile

Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer

NCT02514213

This is a phase I, open-label trial to evaluate the safety and immunogenicity of INO 5150 alone or in combination with INO-9012 when delivered intramuscularly (IM) followed by electroporation (EP) in men with biochemically relapsed prostate cancer.

Prostate Cancer

Inovio Pharmaceuticals62 participantsStarted Jul 2015

Baltimore, Maryland, United States • Detroit, Michigan, United States • Omaha, Nebraska, United States +7 more locations

Study of Recurrent Prostate Cancer With Rising Prostate Specific Antigen (PSA)

Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer

Prostate Cancer Trials in Other Cities

Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery

A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology

Radiation Therapy in Treating Patients With Bone Metastases From Breast or Prostate Cancer

Sildenafil in Treating Erectile Dysfunction in Patients With Prostate Cancer

Sorafenib in Hormone Naïve Biochemical Recurrence of Prostate Cancer

Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors

Ixabepilone in Treating Patients With Metastatic Prostate Cancer

Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer

Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy

A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer

Combination Chemotherapy Plus Filgrastim in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy

Multi-site Decision Impact Study for Decipher

Prostate Biomarker Study

Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer

An Open-label Extension Study of PSMA ADC 2301 in mCRPC

Ketoconazole, Hydrocortisone and Dutasteride in Asymptomatic Hormone Refractory Prostate Cancer

Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer

Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen

Other Conditions in Philadelphia